ArticleFrontiers in cardiovascular medicine2026
Real-world use of theophylline in critically ill patients with sinus pauses: a case series.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A sinus pause is is defined as a delay in sinus node depolarization exceeding 3 s following atrial depolarization. In patients with pauses greater than 5 s accompanied by hemodynamic compromise, the primary treatment is permanent pacemaker (PPM) implantation. However, in the presence of an active infection, alternative strategies such as temporary transvenous pacing or pharmacologic agents may be more appropriate. This report highlights the use of theophylline as a non-invasive therapeutic option in two patients with asymptomatic sinus pauses who had contraindications to PPM placement. Cases: Patient A was a 74-year-old woman with a history of pulmonary arterial hypertension treated with subcutaneous treprostinil and a recent episode of catheter-associated Discussion: Given their active infections, both patients were deemed poor candidates for device placement and were therefore initiated on theophylline. Within 24 h of initiation, the sinus pauses resolved in both patients. Theophylline doses were adjusted to maintain a therapeutic concentration between 10 and 20 µg/mL. Later during hospitalization, Patient A developed atrial fibrillation with rapid ventricular response, prompting discontinuation of theophylline. Patient B was discharged on theophylline 50 mg twice daily, along with a 30-day event monitor and cardiology follow-up. Theophylline exerts its positive chronotropic effects primarily through non-selective phosphodiesterase inhibition and adenosine-1 receptor antagonism. These mechanisms enhance automaticity and reduce atrioventricular node refractoriness, augmenting sinus node automaticity and reducing the frequency and duration of sinus pauses. Conclusion: While these cases highlight the potential role of theophylline as a temporizing pacing strategy, additional research is needed to determine whether and how theophylline can be safely incorporated into treatment protocols for patients who are not suitable for device-based pacing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.